{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:12:30Z","timestamp":1793059950961,"version":"4.5.0"},"reference-count":163,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ando.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T12:19:00Z","timestamp":1534421940000},"page":"618-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Treatment of adult Graves\u2019 disease"],"prefix":"10.1016","volume":"79","author":[{"given":"Bernard","family":"Corvilain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brunaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Orgiazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Bensalem Hachmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Semrouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Rodien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lussey-Lepoutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2018.08.003_bib0820","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1001\/jama.2015.16535","article-title":"Management of Graves disease: a review","volume":"314","author":"Burch","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ando.2018.08.003_bib0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecl.2009.01.009","article-title":"Treatment of Graves\u2019 hyperthyroidism: evidence-based and emerging modalities","volume":"38","author":"Hegedus","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2018.08.003_bib0830","first-page":"2986","article-title":"Graves\u2019 hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study, Thyroid Study Group","volume":"81","author":"Torring","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0835","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0840","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1089\/thy.2015.0277","article-title":"Development and pilot testing of an encounter tool for shared decision making about the treatment of Graves\u2019 disease","volume":"25","author":"Brito","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib0845","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2013-1954","article-title":"Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis","volume":"98","author":"Sundaresh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0850","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"84","author":"Bartalena","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib0855","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0860","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/thy.1998.8.653","article-title":"Quality of life aspects and costs in treatment of Graves\u2019 hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study","volume":"8","author":"Ljunggren","year":"1998","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib0865","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","author":"De Leo","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2018.08.003_bib0870","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/eje.1.02295","article-title":"Remission of Graves\u2019 disease during anti-thyroid drug therapy. Time to reconsider the mechanism?","volume":"155","author":"Laurberg","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib0875","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00625803","article-title":"Comparative in vitro effects and in vivo kinetics of antithyroid drugs","volume":"17","author":"Melander","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ando.2018.08.003_bib0880","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-102-3-328","article-title":"Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance","volume":"102","author":"Cooper","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2018.08.003_bib0885","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.08.003_bib0890","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2265.2012.04365.x","article-title":"Hepatotoxicity and cutaneous reactions after antithyroid drug administration","volume":"77","author":"Otsuka","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib0895","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1572-0241.2001.03469.x","article-title":"The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study","volume":"96","author":"Kim","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ando.2018.08.003_bib0900","doi-asserted-by":"crossref","first-page":"424","DOI":"10.7326\/0003-4819-118-6-199303150-00005","article-title":"Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study","volume":"118","author":"Liaw","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2018.08.003_bib0905","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(16)00113-3","article-title":"Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population","volume":"4","author":"Hallberg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib0910","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1210\/jc.2009-0850","article-title":"Putting propylthiouracil in perspective","volume":"94","author":"Cooper","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0915","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bcp.12336","article-title":"Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study","volume":"78","author":"Wang","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ando.2018.08.003_bib0920","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1089\/thy.2014.0603","article-title":"Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem?","volume":"25","author":"Balavoine","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib0925","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2265.2004.02029.x","article-title":"Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves\u2019 disease","volume":"60","author":"Harper","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib0930","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1365-2265.2001.01282.x","article-title":"Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves\u2019 disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations","volume":"54","author":"Noh","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib0935","first-page":"1516","article-title":"A prospective randomized trial of antithyroid drug dose in Graves\u2019 disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment","volume":"76","author":"Reinwein","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0940","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2265.1995.tb02030.x","article-title":"Response to methimazole in Graves\u2019 disease. The European Multicenter Study Group","volume":"43","author":"Benker","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib0945","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1210\/jcem-63-1-125","article-title":"Treatment of hyperthyroidism with a small single daily dose of methimazole","volume":"63","author":"Shiroozu","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0950","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1046\/j.1365-2265.1996.00800.x","article-title":"A comparison of 20 or 40mg per day of carbimazole in the initial treatment of hyperthyroidism","volume":"45","author":"Page","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib0955","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem-61-2-374","article-title":"Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter","volume":"61","author":"Azizi","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0960","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/thy.2013.0128","article-title":"Global iodine nutrition: where do we stand in 2013?","volume":"23","author":"Pearce","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib0965","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(15)00263-6","article-title":"Iodine deficiency in pregnant women in Europe","volume":"3","author":"Zimmermann","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib0970","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","article-title":"A systematic review of drug therapy for Graves\u2019 hyperthyroidism","volume":"153","author":"Abraham","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib0975","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/cen.12478","article-title":"Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves\u2019 disease: a retrospective observational study","volume":"81","author":"Vaidya","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib0980","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-70-3-675","article-title":"Antithyroid drugs and Graves\u2019 disease: a prospective randomized evaluation of the efficacy of treatment duration","volume":"70","author":"Allannic","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0985","first-page":"337","article-title":"Treatment of Graves\u2019 disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse","volume":"87","author":"Weetman","year":"1994","journal-title":"Q J Med"},{"key":"10.1016\/j.ando.2018.08.003_bib0990","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/jcem-63-1-102","article-title":"Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves\u2019 disease","volume":"63","author":"Chen","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib0995","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-100-3-372","article-title":"Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves\u2019 disease","volume":"100","author":"Takamatsu","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1000","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jcem-64-4-718","article-title":"The mechanism of spontaneous hypothyroidism in patients with Graves\u2019 disease after antithyroid drug treatment","volume":"64","author":"Tamai","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1210\/jcem-69-1-49","article-title":"Development of spontaneous hypothyroidism in patients with Graves\u2019 disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients","volume":"69","author":"Tamai","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1010","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI109601","article-title":"Hypothyroidism as a late sequela in patient with Graves\u2019 disease treated with antithyroid agents","volume":"64","author":"Wood","year":"1979","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2018.08.003_bib1015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MED.0000000000000088","article-title":"Relapse following antithyroid drug therapy for Graves\u2019 hyperthyroidism","volume":"21","author":"Laurberg","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ando.2018.08.003_bib1020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/EJE-14-0704","article-title":"A second course of antithyroid drug therapy for recurrent Graves\u2019 disease: an experience in endocrine practice","volume":"172","author":"Liu","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","article-title":"Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine","volume":"152","author":"Azizi","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1030","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","article-title":"Sustained control of Graves\u2019 hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves\u2019 orbitopathy","volume":"21","author":"Laurberg","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1035","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1089\/thy.2015.0195","article-title":"Outcomes in relapsed Graves\u2019 disease patients following radioiodine or prolonged low dose of methimazole treatment","volume":"25","author":"Villagelin","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1040","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12020-014-0171-8","article-title":"Therapeutic effectiveness of potassium iodine in drug-naive patients with Graves\u2019 disease: a single-center experience","volume":"47","author":"Uchida","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2018.08.003_bib1045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.6065\/apem.2014.19.4.197","article-title":"Effects of short-term potassium iodide treatment for thyrotoxicosis due to Graves disease in children and adolescents","volume":"19","author":"Jeong","year":"2014","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/thy.2014.0084","article-title":"Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38mg\/day and methimazole 30mg\/day as initial therapy for Graves\u2019 disease patients with moderate to severe hyperthyroidism","volume":"25","author":"Sato","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1055","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-2265.2009.03745.x","article-title":"Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves\u2019 disease","volume":"72","author":"Takata","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib1060","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1210\/jc.2013-4466","article-title":"Remission after potassium iodide therapy in patients with Graves\u2019 hyperthyroidism exhibiting thionamide-associated side effects","volume":"99","author":"Okamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1065","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1089\/thy.2014.0581","article-title":"Substituting potassium iodide for methimazole as the treatment for Graves\u2019 disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan","volume":"25","author":"Yoshihara","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12937-015-0116-y","article-title":"Adequacy of iodine intake in three different Japanese adult dietary patterns: a nationwide study","volume":"14","author":"Katagiri","year":"2015","journal-title":"Nutr J"},{"key":"10.1016\/j.ando.2018.08.003_bib1075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1507\/endocrj.44.575","article-title":"Effectiveness of a short-term steroid treatment on the reduction in goiter size in antithyroid drug-treated patients with Graves\u2019 disease","volume":"44","author":"Mori","year":"1997","journal-title":"Endocr J"},{"key":"10.1016\/j.ando.2018.08.003_bib1080","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0140-6736(65)90810-X","article-title":"Remission of hyperthyroidism (Graves\u2019 disease) and altered pattern of serum-thyroxine binding induced by prednisone","volume":"2","author":"Werner","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2018.08.003_bib1085","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1095","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves\u2019 disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/cen.12141","article-title":"The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy","volume":"79","author":"Mitchell","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.08.003_bib1105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-08-0630","article-title":"Rituximab in Graves\u2019 disease","volume":"159","author":"Rodien","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/jc.2009-1655","article-title":"Impact of lithium on efficacy of radioactive iodine therapy for Graves\u2019 disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal","volume":"95","author":"Bogazzi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1125","first-page":"3016","article-title":"The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves\u2019 disease","volume":"86","author":"Burch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02984622","article-title":"Three basic patterns of changes in serum thyroid hormone levels in Graves\u2019 disease during the one-year period after radioiodine therapy","volume":"19","author":"Nakajo","year":"2005","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1135","first-page":"4012","article-title":"Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves\u2019 hyperthyroidism","volume":"84","author":"Andrade","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/MNM.0b013e328324b447","article-title":"Paradoxical exacerbation of preexisting Graves\u2019 disease induced by insufficient radioiodine treatment: a report of five patients","volume":"30","author":"Lee","year":"2009","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ando.2018.08.003_bib1145","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4158\/EP.17.3.456","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"17","author":"Bahn","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2018.08.003_bib1150","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/jc.2006-0226","article-title":"Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial","volume":"91","author":"Bonnema","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/er.2012-1030","article-title":"Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome","volume":"33","author":"Bonnema","year":"2012","journal-title":"Endocrine reviews"},{"key":"10.1016\/j.ando.2018.08.003_bib1160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1530\/EC-15-0119","article-title":"The effect of prior antithyroid drug use on delaying remission in high uptake Graves\u2019 disease following radioiodine ablation","volume":"5","author":"Subramanian","year":"2016","journal-title":"Endocrine connections"},{"key":"10.1016\/j.ando.2018.08.003_bib1165","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bmj.39114.670150.BE","article-title":"Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials","volume":"334","author":"Walter","year":"2007","journal-title":"Bmj"},{"key":"10.1016\/j.ando.2018.08.003_bib1170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MNM.0000000000000414","article-title":"The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study","volume":"37","author":"Chouhan","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ando.2018.08.003_bib1175","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4158\/EP13504.RA","article-title":"Lithium as an adjunct to radioactive iodine for the treatment of hyperthyroidism: a systematic review and meta-analysis","volume":"20","author":"Kessler","year":"2014","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2018.08.003_bib1180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5603\/NMR.2011.0002","article-title":"Lithium carbonate pre-treatment in 131-I therapy of hyperthyroidism","volume":"14","author":"Plazinska","year":"2011","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1016\/j.ando.2018.08.003_bib1185","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2007.02841.x","article-title":"Radioiodine treatment for benign thyroid diseases","volume":"66","author":"Weetman","year":"2007","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1995.tb02039.x","article-title":"Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?","volume":"43","author":"Jarlov","year":"1995","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1195","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","article-title":"A randomized comparison of radioiodine doses in Graves\u2019 hyperthyroidism","volume":"88","author":"Leslie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2362.1995.tb01547.x","article-title":"Radioiodine therapy of Graves\u2019 hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study","volume":"25","author":"Peters","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ando.2018.08.003_bib1205","first-page":"241","article-title":"One-year follow-up of Graves\u2019 disease treatment by four different protocols of radioiodine administration","volume":"42","author":"Calegaro","year":"2000","journal-title":"Panminerva Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1210","first-page":"102","article-title":"Evaluation of long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy (I 131)","volume":"44","author":"Khanna","year":"1996","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.ando.2018.08.003_bib1215","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/00006231-200011000-00014","article-title":"Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: an equivalence study","volume":"21","author":"Kok","year":"2000","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ando.2018.08.003_bib1220","first-page":"322","article-title":"Comparison of the outcome between the calculated dosimetry and the estimated dosimetry of 131I in the treatment of hyperthyroidism","volume":"18","author":"Sun","year":"1995","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.ando.2018.08.003_bib1225","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/BF02985126","article-title":"The incidence of recurrence and hypothyroidism after radioiodine treatment in patients with hyperthyroidism in Trakya, a mild iodine deficiency area, during the period 1991-2003","volume":"19","author":"Ustun","year":"2005","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1230","first-page":"1073","article-title":"High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves\u2019 disease","volume":"87","author":"Alexander","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1235","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1530\/EJE-09-0286","article-title":"Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis","volume":"161","author":"de Rooij","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1240","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2265.2008.03291.x","article-title":"Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism","volume":"70","author":"Boelaert","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0889-8529(05)70307-8","article-title":"Treatment of hyperthyroidism with radioactive iodine","volume":"27","author":"Kaplan","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2018.08.003_bib1250","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/eje.0.1410117","article-title":"Optimized radioiodine therapy of Graves\u2019 disease: analysis of the delivered dose and of other possible factors affecting outcome","volume":"141","author":"Catargi","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1255","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.arcmed.2006.09.007","article-title":"Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage","volume":"38","author":"Hernandez-Jimenez","year":"2007","journal-title":"Arch Med Res"},{"key":"10.1016\/j.ando.2018.08.003_bib1260","first-page":"3611","article-title":"Radioiodine treatment of hyperthyroidism-prognostic factors for outcome","volume":"86","author":"Allahabadia","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1265","doi-asserted-by":"crossref","first-page":"958276","DOI":"10.1155\/2013\/958276","article-title":"Increasing the radioiodine dose does not improve cure rates in severe graves\u2019 hyperthyroidism: a clinical trial with historical control","volume":"2013","author":"Dora","year":"2013","journal-title":"J Thyroid Res"},{"key":"10.1016\/j.ando.2018.08.003_bib1270","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4274\/Mirt.08370","article-title":"Effectiveness of fixed dose Radioactive Iodine (RAI) for the treatment of hyperthyroidism: experience of a teaching hospital in South West Nigeria","volume":"22","author":"Enyi-Ejeh","year":"2013","journal-title":"Mol Imag Radionucl Ther"},{"key":"10.1016\/j.ando.2018.08.003_bib1275","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/1450-1147.98731","article-title":"Radioiodine thyroid ablation in graves\u2019 hyperthyroidism: merits and pitfalls","volume":"11","author":"Nwatsock","year":"2012","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1280","unstructured":"Health protection of individuals against the dangers of ionising radiation in relation to medical exposure, (Council Directive\u00a097\/43 EURATOM 1998), 1998."},{"key":"10.1016\/j.ando.2018.08.003_bib1285","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1007\/s00259-010-1536-8","article-title":"EANM procedure guidelines for therapy of benign thyroid disease","volume":"37","author":"Stokkel","year":"2010","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ando.2018.08.003_bib1290","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2967\/jnumed.112.105148","article-title":"The SNMMI practice guideline for therapy of thyroid disease with\u00a0131I\u00a03.0","volume":"53","author":"Silberstein","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1295","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00259-015-3286-0","article-title":"Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption","volume":"43","author":"Leide-Svegborn","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ando.2018.08.003_bib1300","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00259-016-3326-4","article-title":"Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption","volume":"43","author":"Liepe","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ando.2018.08.003_bib1305","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s002590050438","article-title":"Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism","volume":"26","author":"Barrington","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-005-1888-7","article-title":"Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131","volume":"33","author":"Cappelen","year":"2006","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ando.2018.08.003_bib1315","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1210\/jc.2015-1682","article-title":"Radiation Safety Precautions in (131)I Therapy of Graves\u2019 Disease Based on Actual Biokinetic Measurements","volume":"100","author":"Liu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1320","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0140-6736(05)70454-2","article-title":"Doses in family members after 131I treatment","volume":"350","author":"Mathieu","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2018.08.003_bib1325","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s002590050310","article-title":"Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium)","volume":"25","author":"Monsieurs","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1330","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2967\/jnumed.108.052464","article-title":"131I\u00a0effective half-life and dosimetry in thyroid cancer patients","volume":"49","author":"Remy","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1335","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1210\/jc.2009-2528","article-title":"Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal","volume":"95","author":"Taieb","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1340","first-page":"564","article-title":"Thyroid disease and its treatment: short- and long-term consequences","volume":"33","author":"Franklyn","year":"1999","journal-title":"J R Coll Physicians Lond"},{"key":"10.1016\/j.ando.2018.08.003_bib1345","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1007\/s00259-007-0509-z","article-title":"Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new?","volume":"34","author":"Lucignani","year":"2007","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ando.2018.08.003_bib1350","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.22635","article-title":"Increased cancer incidence after radioiodine treatment for hyperthyroidism","volume":"109","author":"Metso","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2018.08.003_bib1355","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1210\/jc.2006-2321","article-title":"Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism","volume":"92","author":"Metso","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1360","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","article-title":"Cancer mortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy follow-up study group","volume":"280","author":"Ron","year":"1998","journal-title":"Jama"},{"key":"10.1016\/j.ando.2018.08.003_bib1365","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1210\/jc.2007-0837","article-title":"Cardiovascular and cancer mortality after radioiodine treatment of hyperthyroidism","volume":"92","author":"Vanderpump","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1370","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1210\/jc.2015-1874","article-title":"Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism","volume":"100","author":"Ryodi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1375","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1210\/jc.2012-3459","article-title":"Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine","volume":"98","author":"Boelaert","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1380","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0002-9343(99)80137-5","article-title":"Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves\u2019 disease","volume":"99","author":"Uy","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1385","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF00451724","article-title":"Spectrum of quality of life impairment in hypothyroidism","volume":"3","author":"Jaeschke","year":"1994","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ando.2018.08.003_bib1390","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2265.2002.01654.x","article-title":"Psychological well-being in patients on \u2018adequate\u2019 doses of l-thyroxine: results of a large, controlled community-based questionnaire study","volume":"57","author":"Saravanan","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1395","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves\u2019 hyperthyroidism. The Thyroid Study Group","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1400","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","article-title":"Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131","volume":"94","author":"Traisk","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1405","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-15-1099","article-title":"Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves\u2019 hyperthyroidism undergoing radioiodine therapy: a randomized controlled study","volume":"174","author":"Taieb","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1410","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","article-title":"Radioiodine therapy (RAI) for Graves\u2019 disease (GD) and the effect on ophthalmopathy: a systematic review","volume":"69","author":"Acharya","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1415","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2010-2329","article-title":"The dilemma of how to manage Graves\u2019 hyperthyroidism in patients with associated orbitopathy","volume":"96","author":"Bartalena","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1420","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1425","first-page":"542","article-title":"The incidence of ophthalmopathy after radioiodine therapy for Graves\u2019 disease: prognostic factors and the role of methimazole","volume":"79","author":"Kung","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1430","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/thy.2010.1640","article-title":"The tale of radioiodine and Graves\u2019 orbitopathy","volume":"20","author":"Ponto","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1435","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2967\/jnumed.107.049437","article-title":"Radioiodine therapy and Graves\u2019 ophthalmopathy","volume":"49","author":"Sisson","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1440","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1445","article-title":"Radioiodine therapy versus antithyroid medications for Graves\u2019 disease","volume":"2","author":"Ma","year":"2016","journal-title":"The Cochrane database of systematic reviews"},{"key":"10.1016\/j.ando.2018.08.003_bib1450","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000339473","article-title":"Greater efficacy of total thyroidectomy versus radioiodine therapy on hyperthyroidism and thyroid-stimulating immunoglobulin levels in patients with Graves\u2019 disease previously treated with antithyroid drugs","volume":"1","author":"Kautbally","year":"2012","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2018.08.003_bib1455","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1460","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.08.003_bib1465","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrendo.2009.61","article-title":"Graves orbitopathy: a perspective","volume":"5","author":"Perros","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1470","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/thy.2010.1634","article-title":"Risk factors for development or deterioration of Graves\u2019 ophthalmopathy","volume":"20","author":"Stan","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1475","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of Graves\u2019 orbitopathy","volume":"18","author":"Bartalena","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1480","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/eje.1.01938","article-title":"Glucocorticoids and outcome of radioactive iodine therapy for Graves\u2019 hyperthyroidism","volume":"153","author":"Bartalena","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1485","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2009-0506","article-title":"Graves\u2019 orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis","volume":"94","author":"Vannucchi","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1490","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1089\/thy.2014.0218","article-title":"Glucocorticoid regimens for prevention of Graves\u2019 ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis","volume":"24","author":"Shiber","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1495","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1210\/jc.2014-4542","article-title":"Radioiodine-associated exacerbation of Graves\u2019 orbitopathy in the Japanese population: randomized prospective study","volume":"100","author":"Watanabe","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1500","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1210\/jc.2005-0507","article-title":"A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves\u2019 ophthalmopathy","volume":"90","author":"Perros","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1505","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2265.2001.01415.x","article-title":"Graves\u2019 disease, thyroid nodules and thyroid cancer","volume":"55","author":"Belfiore","year":"2001","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1510","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ando.2011.05.003","article-title":"Guidelines of the French society of endocrinology for the management of thyroid nodules","volume":"72","author":"Wemeau","year":"2011","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2018.08.003_bib1515","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/thy.2005.15.1279","article-title":"Graves\u2019 disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery","volume":"15","author":"Abraham-Nordling","year":"2005","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1520","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1210\/jcem-70-4-830","article-title":"Increased aggressiveness of thyroid cancer in patients with Graves\u2019 disease","volume":"70","author":"Belfiore","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1525","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-70-4-826","article-title":"Thyroid cancer and Graves\u2019 disease","volume":"70","author":"Mazzaferri","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1530","first-page":"96","article-title":"Incidental thyroid carcinoma in thyrotoxic patients treated by surgery","volume":"67","author":"Cakir","year":"2007","journal-title":"Horm Res"},{"key":"10.1016\/j.ando.2018.08.003_bib1535","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/bjs.5279","article-title":"Prognosis of small thyroid cancer in patients with Graves\u2019 disease","volume":"93","author":"Kikuchi","year":"2006","journal-title":"Br J Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1545","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00000658-199809000-00005","article-title":"The importance of surgeon experience for clinical and economic outcomes from thyroidectomy","volume":"228","author":"Sosa","year":"1998","journal-title":"Ann Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1550","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000438750","article-title":"The 2015\u00a0European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism","volume":"4","author":"Biondi","year":"2015","journal-title":"Eur Thyroid J."},{"key":"10.1016\/j.ando.2018.08.003_bib1555","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12893-015-0023-3","article-title":"Total thyroidectomy as a method of choice in the treatment of Graves\u2019 disease - analysis of 1432 patients","volume":"15","author":"Bojic","year":"2015","journal-title":"BMC Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1560","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijsu.2015.11.027","article-title":"Thyroid carcinoma in Graves\u2019 disease: a meta-analysis","volume":"27","author":"Staniforth","year":"2016","journal-title":"Int J Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1565","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.surg.2013.10.017","article-title":"A systematic review and meta-analysis of total thyroidectomy versus bilateral subtotal thyroidectomy for Graves\u2019 disease","volume":"155","author":"Feroci","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2018.08.003_bib1570","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0b013e3181d57a59","article-title":"The motor fibers of the recurrent laryngeal nerves are located in the anterior extralaryngeal branch","volume":"251","author":"Barczynski","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1575","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0889-8529(05)70134-1","article-title":"Treatment of Graves\u2019 disease: the advantages of surgery","volume":"29","author":"Alsanea","year":"2000","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2018.08.003_bib1580","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00268-009-0337-3","article-title":"Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves\u2019 disease in the United States","volume":"34","author":"Wilhelm","year":"2010","journal-title":"World J Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1585","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s00268-010-0439-y","article-title":"Five-year follow-up of a randomized clinical trial of unilateral thyroid lobectomy with or without postoperative levothyroxine treatment","volume":"34","author":"Barczynski","year":"2010","journal-title":"World J Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1590","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1210\/jc.2007-0229","article-title":"Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves\u2019 disease","volume":"92","author":"Erbil","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1595","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bjs.1800720118","article-title":"Lugol's iodine: its effect on thyroid blood flow in patients with thyrotoxicosis","volume":"72","author":"Marigold","year":"1985","journal-title":"Br J Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1600","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00268-015-3298-8","article-title":"Effectiveness and mechanism of preoperative lugol solution for reducing thyroid blood flow in patients with euthyroid Graves\u2019 disease","volume":"40","author":"Huang","year":"2016","journal-title":"World J Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1605","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1072-7515(00)00755-9","article-title":"Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter","volume":"191","author":"Ansaldo","year":"2000","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ando.2018.08.003_bib1610","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1245\/s10434-013-3126-z","article-title":"Is potassium iodide solution necessary before total thyroidectomy for Graves disease?","volume":"20","author":"Shinall","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ando.2018.08.003_bib1615","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.beem.2011.10.001","article-title":"Thyroid dermopathy and acropachy","volume":"26","author":"Fatourechi","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.08.003_bib1620","series-title":"EMC, Endocrinologie-Nutrition. 10-003-A-10","article-title":"Hyperthyroidie","author":"Wemeau","year":"2006"},{"key":"10.1016\/j.ando.2018.08.003_bib1625","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/thy.2010.0268","article-title":"Multipoint subcutaneous injection of long-acting glucocorticid as a cure for pretibial myxedema","volume":"21","author":"Deng","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.08.003_bib1630","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/thy.2012.0429","article-title":"Treatment of pretibial myxedema with dexamethazone injected subcutaneously by mesotherapy needles","volume":"23","author":"Vannucchi","year":"2013","journal-title":"Thyroid"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426618312162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426618312162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T16:45:06Z","timestamp":1604767506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426618312162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":163,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0003426618312162"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2018.08.003","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of adult Graves\u2019 disease","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}